CrestecBio, aiming to develop polymer drugs to protect the brain and organs, raises 250 million JPY in seed round
NQ Score
54/100
N1 Content Completeness
10
Key facts
- CrestecBio, aiming to develop polymer drugs to protect the brain and organs, raises 250 million JPY in seed round
- CrestecBio, a startup from the University of Tsukuba, has raised a total of 250 million JPY in its seed round. The company is developing 'CTB211', a neuroprotective drug for ischemic stroke, and will use the funds to accelerate non-clinical trials and manufacturing preparations. The company has also transitioned to a company with a board of directors to strengthen its management structure.
- Source: PR TIMES
- Date: Tue Jun 02 2026 11:00:02 GMT+0900 (Japan Standard Time)
Direct answer
CrestecBio, a startup from the University of Tsukuba, has raised a total of 250 million JPY in its seed round. The company is developing 'CTB211', a neuroprotective drug for ischemic stroke, and will use the funds to accelerate non-clinical trials and manufacturing preparations. The company has also transitioned to a company with a board of directors to strengthen its management structure.
- Citation
- CrestecBio, aiming to develop polymer drugs to protect the brain and organs, raises 250 million JPY in seed round (Tue Jun 02 2026 11:00:02 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Tue Jun 02 2026 11:00:02 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
CrestecBio, a startup from the University of Tsukuba, has raised a total of 250 million JPY in its seed round. The company is developing 'CTB211', a neuroprotective drug for ischemic stroke, and will use the funds to accelerate non-clinical trials and manufacturing preparations. The company has also transitioned to a company with a board of directors to strengthen its management structure.
AI Analysis
Frequently Asked Questions
- Q: What is the significance of CTB211?
- A: It targets reperfusion injury, a major cause of disability after stroke, for which no approved drug currently exists.
- Q: What are the key facts in this article?
- A: CrestecBio, a startup from the University of Tsukuba, has raised a total of 250 million JPY in its seed round. The company is developing 'CTB211', a neuroprotective drug for ischemic stroke, and will use the funds to accelerate non-clinical trials and manufacturing preparations. The company has also transitioned to a company with a board of directors to strengthen its management structure.
- Q: What is the direct answer?
- A: CrestecBio, a startup from the University of Tsukuba, has raised a total of 250 million JPY in its seed round. The company is developing 'CTB211', a neuroprotective drug for ischemic stroke, and will use the funds to accelerate non-clinical trials and manufacturing preparations. The company has also transitioned to a company with a board of directors to strengthen its management structure.